D. E. Shaw Research conducts drug discovery programs both independently and in collaboration with other biopharmaceutical companies and research laboratories. All of our computational work is performed in‑house using a combination of our special‑purpose Anton supercomputers and high‑speed commodity hardware. We do not maintain in‑house “wet lab” facilities, but routinely design experiments for execution under our direction by various specialized contract research organizations (CROs).
Our drug discovery activities fall into three categories, each of which is enabled in part by the use of Anton‑based MD simulations, machine learning methods, and other advanced computational technologies:
Our research, technologies, and pharmaceutical expertise have each played an important role in bringing six drugs into clinical trials. We designed two of these drugs independently; the other four were discovered under a multi‑target collaboration and licensing agreement with Relay Therapeutics (NASDAQ: RLAY), a separate company of which D. E. Shaw Research was a co‑founder.
Our first independently developed drug, DES‑7114, is an orally administered medication that inhibits the ion channel protein Kv1.3 in a highly selective manner. Our preclinical studies demonstrated the efficacy of this first‑in‑class therapeutic in models of several chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn’s disease and atopic dermatitis, and we successfully completed a Phase 1 clinical trial in healthy human volunteers in early 2022. In May 2022, we entered into an exclusive global license agreement with Eli Lilly for further clinical development and commercialization of our program of Kv1.3‑targeted therapeutics, including DES‑7114. Another drug we developed independently, DES‑9384, entered a Phase 1 clinical trial in 2023. DES‑9384 inhibits the ion channel TrpA1, a protein involved in various respiratory and inflammatory diseases (such as chronic cough and rheumatoid arthritis), and in various types of pain (such as arthritic pain, diabetic neuropathy, and chronic lower back pain).
The four drugs on which D. E. Shaw Research collaborated with Relay Therapeutics are all designed for the treatment of cancer. RLY‑4008 targets the receptor tyrosine kinase FGFR2, which is frequently altered in certain malignancies; RLY‑2608 is designed to be the first allosteric, pan‑mutant (H1047X, E542X and E545X) and isoform‑selective PI3Kα inhibitor; RLY‑5836 is a chemically distinct, pan‑mutant and selective PI3Kα inhibitor; and GDC‑1971 (formerly RLY‑1971) is designed to bind and stabilize the protein tyrosine phosphatase SHP2 in its inactive conformation. In December 2020, Relay entered into a worldwide license and collaboration agreement with Genentech for the development and commercialization of GDC‑1971. (To learn more about Relay, click here.)
D. E. Shaw Research welcomes the opportunity to collaborate with other pharmaceutical and biotech companies on the discovery and development of novel therapeutics.